Hard pressed for cash, Cy­cle­ri­on looks for help fund­ing rare dis­ease drug

Cy­cle­ri­on Ther­a­peu­tics may have the de­sign of a Phase IIb study ready to go, but it’s scram­bling for a way to fund it.

The com­pa­ny said in a press re­lease that it’s “ac­tive­ly eval­u­at­ing the best com­bi­na­tion of cap­i­tal, ca­pa­bil­i­ties, and trans­ac­tions avail­able to it to ad­vance the de­vel­op­ment of zago­ciguat,” its lead can­di­date for a rare, ge­net­ic mi­to­chon­dr­i­al dis­ease known as MELAS.

In a sep­a­rate SEC fil­ing, Cy­cle­ri­on once again flagged “sub­stan­tial doubt about (its) abil­i­ty to con­tin­ue as a go­ing con­cern.” As of the end of 2022, it had cash and cash equiv­a­lents of on­ly $13.4 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER